

Charlotte Charpentier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5478491/publications.pdf>

Version: 2024-02-01

201
papers

4,125
citations

126907

33
h-index

182427

51
g-index

217
all docs

217
docs citations

217
times ranked

4928
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine. <i>Journal of Infection</i> , 2022, 84, 248-288.	3.3	6
2	Alpha (B.1.1.7) and Delta (B.1.617.2 " AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage. <i>Journal of Infection</i> , 2022, 84, 418-467.	3.3	4
3	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. <i>Journal of Thoracic Oncology</i> , 2022, 17, 239-251.	1.1	51
4	Omicron SARS-CoV-2 variant: What we know and what we don't. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 100998.	1.4	93
5	Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays. <i>Journal of Infection</i> , 2022, 84, 834-872.	3.3	5
6	Humoral Response to SARS-CoV-2 mRNA Vaccine in Heart Transplant Recipients up to 4 Months After the Third Vaccine Injection. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, S277-S278.	0.6	0
7	Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe. <i>Clinical Infectious Diseases</i> , 2021, 72, 503-509.	5.8	13
8	Influence of gas atmosphere (Ar or He) on the laser powder bed fusion of a Ni-based alloy. <i>Journal of Materials Processing Technology</i> , 2021, 288, 116851.	6.3	33
9	Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. <i>Clinical Microbiology and Infection</i> , 2021, 27, 789.e1-789.e5.	6.0	52
10	A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 214-223.	1.1	3
11	Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 196-204.	3.0	11
12	HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution. <i>Virus Evolution</i> , 2021, 7, veab024.	4.9	5
13	Prevalence of genotypic baseline risk factors for cabotegravir+rilpivirine failure among ARV-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2983-2987.	3.0	14
14	Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements. <i>Journal of Virological Methods</i> , 2021, 291, 114086.	2.1	22
15	HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2306-2309.	3.0	5
16	Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020). <i>Clinical Microbiology and Infection</i> , 2021, 27, 1520.e1-1520.e5.	6.0	12
17	Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2400-2406.	3.0	4
18	Prevalence and factors associated with trichomonas vaginalis infection among female sex workers in Togo, 2017. <i>BMC Infectious Diseases</i> , 2021, 21, 775.	2.9	3

#	ARTICLE	IF	CITATIONS
19	The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> , 2021, 83, e1-e3.	3.3	146
20	Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115430.	1.8	0
21	Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012â€”2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e3266-e3274.	5.8	8
22	In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, , .	3.0	1
23	Prevalence of hepatitis B and C among female sex workers in Togo, West Africa. <i>PLoS ONE</i> , 2021, 16, e0259891.	2.5	5
24	Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 183-193.	3.0	8
25	Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Datâ€™AIDS Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2880-2888.	5.8	10
26	Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106039.	2.5	3
27	Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote dâ€™Ivoire West Africa. <i>PLoS ONE</i> , 2020, 15, e0236642.	2.5	1
28	Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1658.	4.8	2
29	Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3344-3348.	3.0	22
30	Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naïve and -experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1588-1590.	3.0	29
31	New insights in COVID-19â€™associated chilblains: A comparative study with chilblain lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1219-1222.	1.2	36
32	Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravirâ€™+â€™lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1611-1617.	3.0	9
33	M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1290-1293.	3.0	16
34	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1026-1030.	3.0	20
35	Kaposi sarcoma among people living with <sc>HIV</sc> in the French <sc>DAT</sc>â€™<sc>AIDS</sc> cohort between 2010 and 2015. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1065-1073.	2.4	4
36	Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott). <i>Journal of Clinical Virology</i> , 2020, 132, 104618.	3.1	22

#	ARTICLE	IF	CITATIONS
37	Purifying Selection in Human Immunodeficiency Virus-1 <i>pol</i> Gene in Perinatally Human Immunodeficiency Virus-1-Infected Children Harboring Discordant Immunological Response and Virological Nonresponse to Long-Term Antiretroviral Therapy. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 369-376.	1.2	0
38	PD-1/PD-L1 expression in anal squamous intraepithelial lesions. <i>Oncotarget</i> , 2020, 11, 3582-3589.	1.8	6
39	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). <i>Chemical Biology and Drug Design</i> , 2019, 93, 50-59.	3.2	3
40	Short Communication: Extremely Severe CD4 Lymphopenia During HIV-1 Primary Infection. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 930-933.	1.1	0
41	HIV Infection in North African Patients. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 628-633.	1.1	1
42	Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naïve chronically HIV-infected patients in 2015/2016 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1417-1424.	3.0	12
43	Was Zika introduced to Brazil by participants at the 2013 Beach Soccer World Cup held in Tahiti: A phylogeographical analysis. <i>Travel Medicine and Infectious Disease</i> , 2019, 32, 101512.	3.0	1
44	Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1560.e1-1560.e7.	6.0	21
45	Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection. <i>PLoS Pathogens</i> , 2019, 15, e1007758.	4.7	8
46	New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2019-2023.	3.0	8
47	High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2030-2038.	3.0	6
48	Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy. <i>JAMA Dermatology</i> , 2019, 155, 629.	4.1	1
49	New insights are game-changers in HIV-2 disease management. <i>Lancet HIV</i> , 2019, 6, e214.	4.7	1
50	Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naïve and -experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1368-1375.	3.0	11
51	HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1679-1692.	3.0	8
52	Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 754-760.	3.0	41
53	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 614-617.	3.0	23
54	Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 718-721.	3.0	4

#	ARTICLE	IF	CITATIONS
55	Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 739-745.	3.0	67
56	A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain. <i>Clinical Infectious Diseases</i> , 2019, 69, 657-667.	5.8	22
57	Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey. <i>Clinical Infectious Diseases</i> , 2019, 69, 1019-1026.	5.8	25
58	Use of Combination Systemic-Intratatumoral HPV Vaccine to Treat Cutaneous Basaloid Squamous Cell Carcinomas. <i>JAMA Dermatology</i> , 2019, 155, 123.	4.1	2
59	2019 update of the drug resistance mutations in HIV-1. <i>Topics in Antiviral Medicine</i> , 2019, 27, 111-121.	0.1	127
60	Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads. <i>Journal of Virological Methods</i> , 2018, 257, 12-15.	2.1	1
61	Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals. <i>Clinical Infectious Diseases</i> , 2018, 66, 1785-1793.	5.8	4
62	Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1039-1044.	3.0	40
63	Emerging resistance mutations in PI-naïve patients failing an atazanavir-based regimen (ANRS) Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.0	2
64	First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). <i>Clinical Infectious Diseases</i> , 2018, 67, 1161-1167.	5.8	23
65	Minority resistant variants are also present in HIV-2-infected antiretroviral-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1173-1176.	3.0	5
66	High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1665-1671.	3.0	13
67	No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 173-176.	3.0	13
68	Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. <i>PLoS ONE</i> , 2018, 13, e0198334.	2.5	9
69	HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy223.	0.9	2
70	Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)â€‘Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58. <i>Journal of Infectious Diseases</i> , 2018, 218, 1027-1036.	4.0	10
71	Interest of cytology combined with Xpert ^{Â®} HPV and Anyplex ^{Â®} II HPV28 Detection human papillomavirus (HPV) typing: differential profiles of anal and cervical HPV lesions in HIV-infected patients on antiretroviral therapy. <i>HIV Medicine</i> , 2018, 19, 698-707.	2.2	3
72	Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study. <i>Frontiers in Public Health</i> , 2018, 6, 63.	2.7	6

#	ARTICLE	IF	CITATIONS
73	Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. <i>Viruses</i> , 2018, 10, 41.	3.3	27
74	Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2485-2492.	3.0	19
75	Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2716-2720.	3.0	14
76	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. <i>Clinical Infectious Diseases</i> , 2018, 66, 1588-1594.	5.8	15
77	Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw527.	3.0	14
78	Budget impact of antiretroviral therapy in a French clinic cohort. <i>Aids</i> , 2017, 31, 1271-1279.	2.2	17
79	Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1745-1751.	3.0	11
80	Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations. <i>HIV Medicine</i> , 2017, 18, 696-700.	2.2	9
81	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1769-1773.	3.0	27
82	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. <i>EBioMedicine</i> , 2017, 18, 225-235.	6.1	28
83	HIV-1 diagnosis with unquantifiable viraemia: don't be naive, look for antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 630-632.	3.0	2
84	Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. <i>MBio</i> , 2017, 8, .	4.1	71
85	Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. <i>Journal of Clinical Virology</i> , 2017, 96, 49-53.	3.1	27
86	HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir+lamivudine in the maintenance DOLULAM pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2831-2836.	3.0	41
87	Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2954-2955.	3.0	26
88	HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2431-2437.	3.0	7
89	Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 11-16.	1.1	4
90	Diversité génétique des papillomavirus humains. <i>Journal Des Anti-infectieux</i> , 2017, 19, 125-133.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Score for pulmonary tuberculosis in patients with clinical presumption of tuberculosis in a low-prevalence area. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1272-1279.	1.2	4
92	Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. <i>PLoS ONE</i> , 2017, 12, e0180888.	2.5	55
93	Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study. <i>PLoS ONE</i> , 2017, 12, e0172809.	2.5	21
94	Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience. <i>Journal of Medical Virology</i> , 2016, 88, 1204-1210.	5.0	12
95	Hiv-2 molecular epidemiology. <i>Infection, Genetics and Evolution</i> , 2016, 46, 233-240.	2.3	86
96	Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2651-2653.	3.0	5
97	HPV 16 in squamous cell carcinoma of 19th century tonsils. <i>Lancet Oncology</i> , The, 2016, 17, e477-e478.	10.7	3
98	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	9.1	217
99	High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients. <i>Aids</i> , 2015, 29, 779-784.	2.2	11
100	Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. <i>Aids</i> , 2015, 29, 1665-1671.	2.2	43
101	Sustained virological failure in Cameroonesse patient infected by HIV-1 group N evidenced by sequence-based genotyping assay. <i>Aids</i> , 2015, 29, 1267-1269.	2.2	6
102	Tropism distribution among antiretroviral-naive HIV-2-infected patients. <i>Aids</i> , 2015, 29, 2209-2212.	2.2	6
103	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. <i>PLoS ONE</i> , 2015, 10, e0127816.	2.5	3
104	Politique des unités de réanimation pédiatrique francophones concernant l'admission des adolescents. <i>Anesthésie & Réanimation</i> , 2015, 1, 540-546.	0.1	0
105	Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 130-135.	3.0	12
106	Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1517-1521.	3.0	9
107	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1507-1512.	3.0	52
108	Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1881-1884.	3.0	14

#	ARTICLE	IF	CITATIONS
109	Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses. <i>Journal of Virology</i> , 2015, 89, 833-843.	3.4	15
110	Virological failure of patients on maraviroc-based antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1858-64.	3.0	7
111	Pharmacokinetics of Dolutegravir in a Premature Neonate after HIV Treatment Intensification during Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3660-3662.	3.2	27
112	Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2090-2096.	3.0	23
113	Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. <i>Clinical Infectious Diseases</i> , 2015, 60, 1521-7.	5.8	30
114	HIV-2EUâ€”Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1346-1347.	5.8	23
115	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007â€”12: impact on susceptibility to first-line strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2084-2089.	3.0	42
116	Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 475-478.	1.1	2
117	Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up. <i>PLoS ONE</i> , 2015, 10, e0134430.	2.5	4
118	Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. <i>PLoS ONE</i> , 2015, 10, e0134904.	2.5	7
119	Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays. <i>Nigerian Medical Journal</i> , 2015, 56, 420.	0.6	1
120	Evaluation of Four Tenofovir-Containing Regimens as First-Line Treatments in Cameroon and Senegal: The Anrs 12115 Dayana Trial. <i>Antiviral Therapy</i> , 2014, 19, 51-59.	1.0	13
121	Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment. <i>Journal of the International AIDS Society</i> , 2014, 17, 19744.	3.0	0
122	Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2588-2590.	3.0	2
123	Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2819-2825.	3.0	9
124	Short Communication: Prevalence of HIV-1 Transmitted Drug Resistance in Liberia. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 863-866.	1.1	7
125	Genotypic resistance profiles of HIV-2-treated patients in West Africa. <i>Aids</i> , 2014, 28, 1161-1169.	2.2	43
126	HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients. <i>Aids</i> , 2014, 28, 2160-2162.	2.2	6

#	ARTICLE	IF	CITATIONS
127	Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naïve patients failing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1086-1089.	3.0	18
128	NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment. <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 103-106.	2.2	1
129	Longitudinal analysis of integrase Δ 155H variants in heavily treated patients failing raltegravir-based regimens. <i>HIV Medicine</i> , 2013, 14, 85-91.	2.2	7
130	Update on the Human Immunodeficiency Virus. <i>Médecine Et Maladies Infectieuses</i> , 2013, 43, 177-184.	5.0	9
131	Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in France. <i>Aids</i> , 2013, 27, 2309-2312.	2.2	23
132	Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. <i>Aids</i> , 2013, 27, 292-295.	2.2	7
133	HIV-2EU: Supporting Standardized HIV-2 Drug Resistance Interpretation in Europe. <i>Clinical Infectious Diseases</i> , 2013, 56, 1654-1658.	5.8	31
134	Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2197-8.	3.0	14
135	Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naïve patients infected with B and non-B subtype HIV-1 viruses. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1237-1242.	3.0	42
136	Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2199-2204.	3.0	7
137	Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1428-1433.	3.9	3
138	Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 690-696.	3.0	13
139	National sentinel surveillance of transmitted drug resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade: 2001-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2626-2631.	3.0	41
140	High Rate Of Antiretroviral Drug Resistance Mutations in HIV Type 1-Infected Senegalese Children in Virological Failure on First-Line Treatment According to the World Health Organization Guidelines. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 242-249.	1.1	33
141	Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naïve HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 758-765.	3.2	14
142	Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients. <i>Aids</i> , 2013, 27, 69-80.	2.2	6
143	In-vitro phenotypic susceptibility of HIV-1 Δ non-B integrase inhibitors naïve clinical isolates to dolutegravir and raltegravir. <i>Aids</i> , 2013, 27, 2959-2961.	2.2	6
144	Transmitted drug resistance in French HIV-2-infected patients. <i>Aids</i> , 2013, 27, 1671-1674.	2.2	12

#	ARTICLE	IF	CITATIONS
145	Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial). PLoS ONE, 2013, 8, e53621.	2.5	6
146	Description of the L76V Resistance Protease Mutation in HIV-1 B and "Non-B" Subtypes. PLoS ONE, 2013, 8, e54381.	2.5	1
147	Predictive Value of Liver Enzymes and Inflammatory Biomarkers for the Severity of Liver Fibrosis Stage in HIV/HCV Co-Infected Patients. PLoS ONE, 2013, 8, e59205.	2.5	10
148	<i>In Vitro</i> Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors. Antimicrobial Agents and Chemotherapy, 2012, 56, 137-139.	3.2	28
149	Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. Journal of Antimicrobial Chemotherapy, 2012, 67, 2231-2235.	3.0	41
150	Virological Response and Resistance Profiles After 24 Months of First-Line Antiretroviral Treatment in Adults Living in Bangui, Central African Republic. AIDS Research and Human Retroviruses, 2012, 28, 315-323.	1.1	25
151	Prevalence of subtype-related polymorphisms associated with <i>in vitro</i> resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B' infected patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 1459-1461.	3.0	24
152	Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic. AIDS Research and Human Retroviruses, 2012, 28, 87-94.	1.1	31
153	Molecular Determinants of HIV-2 R5-X4 Tropism in the V3 Loop: Development of a New Genotypic Tool. Journal of Infectious Diseases, 2012, 205, 111-120.	4.0	44
154	Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. Journal of Antimicrobial Chemotherapy, 2012, 67, 1475-1478.	3.0	24
155	Association of Soluble CD14 and Inflammatory Biomarkers With HIV-2 Disease Progression. Clinical Infectious Diseases, 2012, 55, 1417-1425.	5.8	24
156	Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm ³ at the time of diagnosis according to HIV-1 coreceptor tropism. Journal of Medical Virology, 2012, 84, 1853-1856.	5.0	7
157	Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. Journal of Antimicrobial Chemotherapy, 2012, 67, 2487-2493.	3.0	4
158	Variants résistants mineurs VIH-2: détection, prévalence et impact sur la réponse virologique. Journal Des Anti-infectieux, 2012, 14, 20-26.	0.1	0
159	Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 129-133.	2.9	5
160	Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Scandinavian Journal of Infectious Diseases, 2011, 43, 373-379.	1.5	7
161	Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen. Aids, 2011, 25, 2143-2148.	2.2	4
162	Surveillance of Antiretroviral Drug Resistance Mutations in Untreated Young Children Living in the Central African Republic. Antiviral Therapy, 2011, 16, 1347-1350.	1.0	9

#	ARTICLE	IF	CITATIONS
163	Residual HIV-1 RNA and HIV-1 Dna Production in the Genital Tract Reservoir of Women Treated with Haart: The Prospective Anrs Ep24 Gynodyn Study. <i>Antiviral Therapy</i> , 2011, 16, 843-852.	1.0	36
164	High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger. <i>Antiviral Therapy</i> , 2011, 16, 429-433.	1.0	23
165	Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. <i>Antiviral Therapy</i> , 2011, 16, 937-940.	1.0	8
166	Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene. <i>HIV Medicine</i> , 2011, 12, 138-144.	2.2	7
167	Usefulness of a genotypic resistance test using dried blood spot specimens in African HIV-infected children with virological failure according to the 2010-revised WHO criteria. <i>Archives of Virology</i> , 2011, 156, 1603-1606.	2.1	12
168	Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. <i>Future Microbiology</i> , 2011, 6, 731-737.	2.0	7
169	Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1972-1975.	3.0	14
170	Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1582-1589.	3.0	11
171	Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1293-1295.	3.2	29
172	The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2827-2830.	3.0	43
173	Positive Impact of HIV-1 gag Cleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1754-1757.	3.2	10
174	Virological Failure and HIV Type 1 Drug Resistance Profiles Among Patients Followed-up in Private Sector, Douala, Cameroon. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 221-230.	1.1	10
175	Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. <i>Journal of Infection in Developing Countries</i> , 2011, 5, 064-067.	1.2	9
176	In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. <i>Aids</i> , 2010, 24, 2753-2755.	2.2	31
177	High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. <i>Aids</i> , 2010, 24, 867-873.	2.2	38
178	Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. <i>Aids</i> , 2010, 24, 2651-2656.	2.2	16
179	Darunavir resistance spectrum in darunavir-naïve patients harboring virological failure to antiretroviral therapy. <i>Journal of the International AIDS Society</i> , 2010, 13, P133.	3.0	1
180	Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens. <i>Journal of the International AIDS Society</i> , 2010, 13, P136-P136.	3.0	0

#	ARTICLE	IF	CITATIONS
181	Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure. <i>Transplant Infectious Disease</i> , 2010, 12, 213-219.	1.7	19
182	Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy. <i>Infection and Drug Resistance</i> , 2010, 3, 103.	2.7	1
183	Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4016-4019.	3.2	19
184	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naïve chronically HIV-infected patients from 2001 to 2006/2007 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2620-2627.	3.0	62
185	Gag Mutations Can Impact Virological Response to Dual-Boosted Protease Inhibitor Combinations in Antiretroviral-Naïve HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2910-2919.	3.2	28
186	Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 72-77.	3.2	33
187	Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3335-3340.	3.2	65
188	Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. <i>Journal of Clinical Virology</i> , 2010, 47, 79-81.	3.1	23
189	Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4522-4524.	3.2	46
190	High Frequency of Antiretroviral Drug Resistance among HIV-Infected Adults Receiving First-Line Highly Active Antiretroviral Therapy in Niamey, Chad. <i>Clinical Infectious Diseases</i> , 2009, 49, 155-159.	5.8	31
191	In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1192-1195.	3.0	12
192	Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy*. <i>HIV Medicine</i> , 2008, 9, 765-770.	2.2	95
193	Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients. <i>Journal of Clinical Virology</i> , 2008, 43, 212-215.	3.1	9
194	Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3237-3243.	3.2	45
195	Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1362-1368.	3.0	14
196	Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral Treatment. <i>Journal of Virology</i> , 2007, 81, 7620-7628.	3.4	103
197	Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. <i>Aids</i> , 2007, 21, 153-162.	2.2	26
198	Extensive Recombination among Human Immunodeficiency Virus Type 1 Quasispecies Makes an Important Contribution to Viral Diversity in Individual Patients. <i>Journal of Virology</i> , 2006, 80, 2472-2482.	3.4	102

#	ARTICLE	IF	CITATIONS
199	Low Genetic Barrier to Large Increases in HIV-1 Cross-Resistance to Protease Inhibitors during Salvage Therapy. <i>Antiviral Therapy</i> , 2006, 11, 143-154.	1.0	19
200	Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors. <i>Journal of Virology</i> , 2004, 78, 4234-4247.	3.4	76
201	A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. <i>Human Mutation</i> , 2000, 15, 486-486.	2.5	10